Literature DB >> 14659807

Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.

Derek J Hausenloy1, Michael R Duchen, Derek M Yellon.   

Abstract

OBJECTIVE: The opening of the mitochondrial permeability transition pore (mPTP) in the first few minutes of post-ischaemic reperfusion is a critical determinant of reperfusion-induced cell death. We hypothesised that the novel immunosuppressant, sanglifehrin-A (SFA), given at the time of reperfusion, protects the myocardium from ischaemia-reperfusion injury, by suppressing mPTP opening.
METHODS: Isolated perfused rat hearts were subjected to 35 min ischaemia/120 min reperfusion, and were treated with (1) SFA (1.0 microM) or (2) DMSO vehicle for the first 15 min of reperfusion or (3) SFA (1.0 microM) after the first 15 min of reperfusion. We examined the effect of SFA on mPTP opening directly, using a myocyte model of oxidative stress. Laser illumination of adult rat myocytes loaded with the fluorophore, TMRM, generates oxidative stress, which induces mPTP opening (represented by mitochondrial membrane depolarisation) followed by rigour contracture.
RESULTS: In the isolated perfused heart model, SFA, given during the first 15 min of post-ischaemic reperfusion, reduced the infarct-risk volume ratio from 43.9+/-2.5% in the control group to 23.8+/-4.2% with SFA (p=0.001). However, when SFA was given after the first 15 min of reperfusion, there was no change in infarct size (43.8+/-5.7% with SFA vs. 43.9+/-2.5% in control; p=NS), suggesting that SFA has to be present during the first 15 min of reperfusion to induce protection. In the isolated adult myocyte model, SFA was shown to inhibit mPTP opening in the setting of oxidative stress, represented by an increase in the ROS threshold required to induce: mitochondrial membrane depolarisation (from 269+/-21 to 777+/-100 s; p<0.001) and rigour contracture (from 613+/-14 to 1329+/-129 s; p<0.001).
CONCLUSIONS: Inhibiting mPTP opening during the first few minutes of reperfusion, using sanglifehrin-A, limits infarct size and protects myocytes from oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14659807     DOI: 10.1016/j.cardiores.2003.09.025

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  124 in total

1.  Low-intensity aerobic interval training attenuates pathological left ventricular remodeling and mitochondrial dysfunction in aortic-banded miniature swine.

Authors:  Craig A Emter; Christopher P Baines
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-03       Impact factor: 4.733

Review 2.  Mitochondrial morphology and cardiovascular disease.

Authors:  Sang-Bing Ong; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2010-07-14       Impact factor: 10.787

Review 3.  Mechanisms of cell death in heart disease.

Authors:  Klitos Konstantinidis; Russell S Whelan; Richard N Kitsis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-17       Impact factor: 8.311

4.  The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore.

Authors:  S Y Lim; S M Davidson; M M Mocanu; D M Yellon; C C T Smith
Journal:  Cardiovasc Drugs Ther       Date:  2007-12       Impact factor: 3.727

5.  Short term administration of L-carnitine can be detrimental to the ischemic heart.

Authors:  Moslem Najafi; Alireza Garjani
Journal:  Adv Pharm Bull       Date:  2013-12-23

6.  Proteomic analysis of mitochondrial proteins in cardiomyocytes from rats subjected to intermittent hypoxia.

Authors:  Wei-Zhong Zhu; Xiu-Feng Wu; Yi Zhang; Zhao-Nian Zhou
Journal:  Eur J Appl Physiol       Date:  2011-07-07       Impact factor: 3.078

7.  Mitochondrial Ca2+ influx and efflux rates in guinea pig cardiac mitochondria: low and high affinity effects of cyclosporine A.

Authors:  An-Chi Wei; Ting Liu; Sonia Cortassa; Raimond L Winslow; Brian O'Rourke
Journal:  Biochim Biophys Acta       Date:  2011-02-26

Review 8.  The molecular composition of the mitochondrial permeability transition pore.

Authors:  Christopher P Baines
Journal:  J Mol Cell Cardiol       Date:  2009-02-20       Impact factor: 5.000

Review 9.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

Review 10.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.